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Abstract. Tumor-specificity (TS) and anti-inflammatory
activity of benzo[b]cyclohept[e][1,4]oxazin-6(11H)-one,
generally known as benzoxazinotropone (BOT), have been
reported. In order to find a new biological activity, the
combination effect of BOT and three apoptosis-inducing
agents was investigated. Cytotoxicity against four human
oral squamous cell carcinoma (OSCC) cell lines and five
human oral normal cells (gingival fibroblasts, periodontal
ligament fibroblasts, pulp cells, oral keratinocytes and
primary gingival epithelial cells) was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
method. TS was evaluated by the ratio of the mean 50%
cytotoxic concentration (CC50) against normal oral cells to
the one against OSCC cell lines. Synergy was evaluated by
CompuSyn software program. Expression of cleaved forms
of poly ADP-ribose polymerase and caspsase-3 was
evaluated by western blot analysis. BOT induced activation
of caspase 3, suggesting the apoptosis induction in HSC-2
OSCC cells. BOT enhanced the cytotoxicity of doxorubicin
(DXR) additively and that of curcumin and resveratrol
synergistically. On the other hand, BOT did not enhance, but
rather inhibit the cytotoxicity of DXR against normal
keratinocytes. The present study suggests that BOT may
enhance the anti-tumor activity of apoptosis-inducing agents,
while reducing its cytotoxicity against normal cells.
Heterocylic compounds are known to display diverse
biological activities (1). Hinokitiol and its related derivatives
with a tropolone skeleton (2-4) have been reported to exhibit
various biological activities, such as antimicrobial (5),
antifungal (6) and phytogrowth-inhibitory activity (7, 8),
cytotoxic effects on mammalian tumor cells (9, 10) and
inhibitory effects on catechol-O-methyltransferase (11) and
metalloproteases (5). Hinokitiol acetate did not exhibit
cytotoxic activity (10), antimicrobial activity nor
metalloprotease inhibition (5), suggesting that these biological
effects of hinokitiol-related compounds may result from the
formation of metal chelates by the carbonyl group at C-1 with
the hydroxyl group at C-2 in the tropone skeleton. 
We have recently reported that benzo[b]cyclohept[e]
[1,4]oxazin-6(11H)-one (here referred to as benzoxazino-
tropone (BOT)) (structure shown in Figure 1) showed
slightly (2.2-fold) higher cytotoxicity against human oral
squamous cell carcinoma (OSCC) cell lines (HSC-2, HSC-
3, HSC-4) than human mesenchymal normal oral cells
(human gingival fibroblasts (HGF); human periodontal
ligament fibroblasts (HPLF); human pulp cells (HGF)) (12)
(Table I) and potently inhibited the production of nitric oxide
by lipopolysaccharide-activated mouse macrophage-like
RAW264.7 cells via inhibition of inducible nitric oxide
synthase and cyclooxygenase-2 protein expression (13). In
order to obtain more information of its antitumor potential,
we investigated here whether BOT induces apoptosis in
HSC-2 cells and whether BOT potentiates cytotoxicity of
apoptosis-inducing agents, that is, doxorubicin (DXR), an
anthracycline antitumor antibiotic (14), curcumin, a natural
component of the rhizome of turmeric (15) and resveratrol,
a class of polyphenolic compounds called stilbenes (16)
against HSC-2 cells, but not against human oral
keratinocytes (HOK).
Cytotoxicity of these compounds was evaluated using both
human normal oral cells derived from mesenchymal (HGF,
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HPLF, HPC) and epithelial tissues (HOK, primary human
gingival epithelial cells (HGEP)), as well as human (OSCC)
cell lines (Ca9-22, HSC-2, HSC-3, HSC-4). The tumor-
selectivity index (TS) was calculated by dividing the mean
50% cytotoxic concentration (CC50) against normal oral cells
by that against OSCC cell lines. We have already
demonstrated that the TS value determined by this method
reflects the antitumor potential of test compounds, although
these normal oral cells and OSCC cell lines are classified as
different types of cells (mesenchymal or epithelial) (17). 
Materials and Methods
Materials. The following chemicals and reagents were obtained
from the indicated companies: Dulbecco’s modified Eagle’s medium
(DMEM) from GIBCO BRL, Grand Island, NY, USA; fetal bovine
serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), doxorubicin-HCl (DXR), resveratrol from Sigma-
Aldrich Inc., St. Louis, MO, USA; dimethyl sulfoxide (DMSO)
from Wako Pure Chem. Ind., Osaka, Japan; curcumin from Tokyo
Kasei Kogyo Co., Tokyo, Japan); 5-fluorouracil (5-FU) from
Kyowa, Tokyo, Japan; Culture plastic dishes and plates (96-well)
were purchased from Becton Dickinson (Franklin Lakes, NJ, USA).
Benzoxazinotropone (BOT) was synthesized by the reaction of 3-
bromo-2-methoxytropone with o-aminophenol as described
previously (18, 19). BOT, doxorubicin, curcumin and resveratrol
were dissolved in DMSO at 80, 1, 40, 40 mM and stored at –20˚C
before use. Protease and phosphatase inhibitors were purchased
from Roche Diagnostics (Tokyo, Japan). Antibodies against cleaved
caspase-3 (Cell Signaling Technology Inc., Beverly, MD, USA),
PARP (Cell Signaling Technology Inc.) and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (Trevigen, Gaithersburg, MD,
USA) were used as primary antibodies. As secondary antibodies, α-
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Table I. Cytotoxic activity of BOT, curcumin, resveratrol and 5-FU. Each value represents the mean±S.D. of three independent experiments performed
in triplicate, except for 5-FU (just one experiment performed in triplicate). 
                                                                                                                                CC50 (μM)
                                    BOT                 Curcumin                    (SD)                    Resveratrol                   (SD)                       5-FU                     (SD)
HSC-2                          163.0                      8.1                          1.0                            76.7                         28.6                         27.2                     26.6 
HSC-3                          152.0                      7.6                          3.7                            65.2                         12.2                         20.8                      7.5 
HSC-4                          206.0                     13.4                         4.0                            72.6                          6.5                          33.8                     29.3 
Ca9-22                         174.0                     11.2                         3.8                           146.9                        27.7                        226.7                   272.0 
A (mean)                                                     10.1                         2.2                            90.4                         16.0                         77.1                     65.1 
                                                                                                                                                                                                                                         
HGF                             341.0                     46.5                         3.8                           287.0                        12.9                        >1000                        
HPLF                           423.0                     34.3                         4.2                           261.9                        11.9                        892.7                        
HPC                             408.0                     36.9                         3.3                           266.2                        18.6                        879.4                        
B (mean)                      391.0                     39.3                         3.7                           277.0                         9.5                        >928.6                       
                                                                                                                                                                                                                                         
HOK                                                            12.9                        10.6                          124.3                        42.8                        330.2                   435.5 
HGEP                                                          16.7                         8.5                           114.9                        17.7                         97.1                    135.7 
C (mean)                                                     14.8                         1.1                           119.6                        30.2                        231.7                   302.8 
                                                                                                                                                                                                                                         
TS value                                                                                                                                                                                                                           
B/A                                 2.2                        3.9                                                             3.1                                                          >12.0                        
C/A                                                               1.5                                                             1.3                                                            3.0                          
HGF, Human gingival fibroblasts; HPC, human pulp cells; HPLF, human periodontal ligament fibroblasts; Ca9-22, HSC-2, HSC-3 and HSC-4,
human oral squamous cell carcinoma cell lines; HOK, human oral keratinocytes; HGEP, primary human gingival epithelial cells; TS; tumor selectivity
index; CC50, 50% cytotoxic concentration; BOT, benzo[b]cyclohept[e][1,4]oxazin-6(11H)-one; 5-FU, 5-fluorouracil. Data on BOT cytotoxicity were
cited from our previous publication (12).
Figure 1. Structure of tropone and benzo[b]cyclohept[e][1,4]oxazin-
6(11H)-one (BOT).
rabbit IgG (DAKO Japan) antibodies, which were conjugated with
horseradish peroxidase, were used.
Cell culture. HGF, HPLF and HPC cells, established from the first
premolar tooth extracted from the lower jaw of a 12-year-old girl
(20) and OSCC cell lines (Ca9-22, HSC-2, HSC-3, HSC-4)
purchased from Riken Cell Bank, Tsukuba, Japan were cultured at
37˚C in DMEM supplemented with 10% heat-inactivated FBS, 100
units/ml penicillin G and 100 μg/ml streptomycin sulfate under a
humidified 5% CO2 atmosphere. HOK (purchased from COSMO
BIO Co/ Ltd., Tokyo, Japan) was cultured in keratinocyte growth
supplement (OKGS, Cat, No. 2652; Science Research laboratories,
Carlsbad, CA, USA). Primary human gingival epithelial cells
(HGEP) (purchased from CELLnTEC Advanced Cell Systems AG,
Bern, Switzerland) were grown in CnT-PR medium (CELLnTEC).
Cells were then harvested by treatment with 0.25% trypsin-0.025%
EDTA-2Na in phosphate-buffered saline without calcium and
magnesium [PBS(−)] and subcultured or used for experiments.
Assay for cytotoxic activity. Cells were inoculated at 2.5×103
cells/0.1 ml in a 96-microwell plate (Becton Dickinson Labware,
Franklin Lakes, NJ, USA). After 48 hours, the medium was
removed by suction with an aspirator and replaced with 0.1 ml of
fresh medium containing different concentrations of test compounds
in single or in combination with BOT. Control cells were treated
with the same amounts of DMSO present in each diluent solution.
Cells were incubated for 48 hours and the relative viable cell
number was then determined by the MTT method. In brief, the
treated cells were incubated for another 3 hours in fresh culture
medium containing 0.2 mg/ml MTT. Cells were then lysed with 0.1
ml of DMSO and the absorbance at 540 nm of the cell lysate was
determined using a microplate reader (Sunrise Rain bow RC-R;
TECAN, Mannedorf Switzerland). The CC50 was determined from
the dose–response curve and the mean CC50 for each cell type was
calculated from three independent experiments.
Calculation of TS. When normal oral mesenchymal cells (HGF,
HPLF, HPC) were used, TS was calculated by the following
equation: TS=mean CC50 against HGF, HPLF and HPC cells / mean
CC50 against OSCC cell lines (shown as (B/A) in Table I).
When normal oral epithelial cells (HOK, HGEP) were used, TS
was calculated by the following equation: TS=mean CC50 against
HOK and HGEP/mean CC50 against OSCC cell lines (shown as
(C/A) in Table I). 
Western blot analysis. The cells were washed with phosphate-
buffered saline (PBS) and re-suspended in 50 mM Tris-HCl (pH 7.6),
150 mM NaCl, 1 mM EDTA, 0.1% sodium dodecyl sulfate (SDS),
0.5% deoxycholic acid, 1% NP-40 and protease inhibitors (RIPA
buffer). After ultrasonication using Bioruptor (UCD-250; Cosmo
Bio) for 12.5 min (10 sec on, 20 sec off) at the middle level of output
(250 W) at 4˚C, the soluble cellular extracts were recovered after
centrifugation for 10 min at 16,000 × g. The protein concentration
of each sample was determined using the BCA Protein Assay
Reagent Kit (Thermo Fisher Scientific) and cell extracts were
subjected to Western blot (WB) analysis. The blots were probed with
the primary antibody followed by a horseradish peroxidase-
conjugated secondary antibody. The immune complexes were
visualized using Pierce Western Blotting Substrate Plus (Thermo
Fisher Scientific). WB results were documented and quantified using
ImageQuant LAS 500 (GE Healthcare, Tokyo, Japan).
Statistical treatment. Each experimental value is expressed as the
mean±standard deviation (SD) of three independent experiments
that were performed in triplicate in most of experiments. The
CompuSyn software program (ComboSyn, Inc., Paramus, NJ, USA)
was used to calculate the combination index (CI) (21). Briefly, CI
value was determined by the following equation: CI=(% decrease
of viable cell number by compound A + % decrease of viable cell
number by compound B)/(% decrease of viable cell number by
combination of compound A and B). The combination effect was
judged “synergistic”, “additive” or “antagonistic” when CI is <1, 1
and >1, respectively. 
Results
Apoptosis induction. WB analysis demonstrated that BOT
dose-dependently induced the activation of caspase 3
(detected by the active form of caspase 3, that is, cleaved
Tomikoshi et al: Enhancement of Antitumor Activity by Benzoxazinotropone
647
Figure 2. Induction of apoptosis markers by benzo[b]cyclohept[e][1,4]oxazin-6(11H)-one (BOT) in human OSCC HSC-2 cells. Near-confluent HSC-
2 cells were incubated for 24 h with the indicated concentrations (25~400 μM) of BOT and expression of cleaved products of PARP and caspase-3
was visualized by western blot analysis. Each sample contains 0.1% DMSO. Act, Actinomycin D (2 μM), was used as an apoptosis-positive control.
caspase and the cleavage of PARP, one of the substrates of
caspase 3) (22). The effects of BOT became discernible
above 25 μM and reached plateau at 50~400 μM. These
results suggest that BOT induced apoptosis in HSC-2 cells
but at a slightly lower level than that achieved by
actinomycin D, a positive control of apoptosis (Figure 2). 
Combination with DXR. DXR (0.02~5 μM) dose-
dependently reduced the viable cell numbers of HSC-2 cells,
while addition of increasing concentrations (12.5~200 μM)
of BOT further reduced the viable cell numbers of HSC-2
cells (Figure 3A). Calculation of combination index (CI)
revealed that lower concentrations (12.5 and 25 μM) of BOT
showed a somewhat additive effect (CI=1), whereas higher
concentrations were rather antagonistic (CI>1) (Figure 3B). 
DXR showed bi-phasic effect on growth of HOK cells,
known as hormesis (23), stimulating the growth at lower
concentrations and inhibiting the growth at higher
concentrations (Figure 4). Simultaneous addition of BOT did
not enhance, but rather tended to inhibit, the cytotoxicity of
DXR (Figure 4). This suggests that BOT protected the cells
from DXR-induced cytotoxicity. 
Combination with curcumin and resveratrol. Since there was
no detailed study of tumor-specificity of curcumin and
resveratrol, we first investigated their cytotoxicity against
human oral OSCC (Ca9-22, HSC-2, HSC-3, HSC-4) and
human oral normal cells (HGF, HPLF, HPC, HOK, HGEP)
(Table I). We found that curcumin and resveratrol gave TS
(B/A) values of 3.9 and 3.1, respectively, about 3~4-fold less
than that of 5-FU (TS>12.0) when normal mesenchymal
cells (HGF, HPLF, HPC) were used (Table I). These
polyphenols gave very low TS (C/A) values of 1.5 and 1.3,
respectively, about one half that of 5-FU (TS=3.0), when
normal epithelial cells (HOK, HGEP) were used (Table I).
We next investigated the combination effect of BOT and
these polyphenols. BOT and curcumin or resveratrol gave
additive cytotoxic effects on the growth of HSC-2 cells
(Figure 5A and B). In particular, when the concentrations of
these polyphenols were below 12.5 μM, synergistic
inhibition of the growth of HSC-2 cells was observed. 
Discussion
The present study demonstrated, for the first time, that
relatively lower concentrations (12.5 and 25 μM) of BOT
enhances the cytotoxicity of DXR against OSCC cells (HSC-
2) in an additive fashion, while BOT slightly protected HOK
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Figure 4. Protective effect of benzo[b]cyclohept[e][1,4]oxazin-6(11H)-
one (BOT) on doxorubicin (DXR)-induced cytotoxicity against HOK
cells. HOK cells were incubated for 48 h with the indicated
concentrations (0.02~5 μM) of DXR in the presence of 12.5, 25, 50, 100
or 200 μM of BOT and, then, viable cell number was determined by
MTT method. Each value represents mean of triplicate assays.
Figure 3. Combination effect of doxorubicin and benzo[b]
cyclohept[e][1,4]oxazin-6(11H)-one (BOT) on the viable cell number of
HSC-2 cells. (A) Near-confluent HSC-2 cells were incubated for 48 h
with the indicated concentrations (0.02~5 μM) of doxorubicin (DXR) in
the presence of 12.5, 25, 50, 100 or 200 μM of BOT and, then, viable
cell number was determined by MTT method. Each value represents
mean of three independent experiments. (B) Combination index (CI), as
calculated from data of A.
cells from the cytotoxicity of DXR. This suggests that
appropriate concentrations of BOT may potentiate the
antitumor action of DXR.
The other new finding of the present study is that BOT
dose-dependently enhanced the cytotoxicity of curcumin
and resveratrol against HSC-2 cells, additively or
synergistically (Figure 5). Additivity was found when
relatively higher concentrations of curcumin (25~200 μM)
and resveratrol (12.5~200 μM) were used, whereas
synergy was observed when relatively lower
concentrations of curcumin (3.1~12.5 μM) and resveratrol
(3.1~6.3 μM) were employed. The biological significance
of the present study is unclear. Further study is needed to
discriminate whether the present finding is unique only to
BOT or universally observed in all benzoxazinotropone
family. 
We recently reported that human oral epithelial cells
(HOK, HGEP) were highly sensitive to DXR and 5-FU (24-
26). This finding was supported by the present study. Studies
are underway to search for natural and/or synthetic
compounds that alleviate the cytotoxicity of these antitumor
agents against normal oral epithelial cells. 
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